PURE Bioscience Management
Management criteria checks 2/4
PURE Bioscience's CEO is Jeff Kitchell, appointed in Jan 2019, has a tenure of 7.58 years. directly owns 0.01% of the company’s shares, worth $999.58. The average tenure of the management team and the board of directors is 3.6 years and 5.6 years respectively.
Key information
Jeff Kitchell
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.6yrs |
| CEO ownership | 0.01% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO
Jeff Kitchell
Mr. Jeff Kitchell was Vice President of Operations of PURE Bioscience, Inc. until November 17, 2025 and serves as its President since November 17, 2025 and serves as its Corporate Secretary since 2019 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP of Finance and Principal Financial & Accounting Officer | 11.1yrs | US$178.60k | 0.056% $ 5.6k | |
| Executive VP of Technology & Development and Director | 3.6yrs | US$197.40k | 0.65% $ 65.4k | |
| Director & Advisor | less than a year | US$191.30k | 0.038% $ 3.8k | |
| President | 7.6yrs | no data | 0.010% $ 999.6 | |
| Vice President of Operations & & Regulatory Affairs | less than a year | no data | no data | |
| Vice President of Sales & Marketing | no data | no data | no data |
Experienced Management: PURE's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP of Technology & Development and Director | 5.6yrs | US$197.40k | 0.65% $ 65.4k | |
| Director & Advisor | 3.5yrs | US$191.30k | 0.038% $ 3.8k | |
| President | no data | no data | 0.010% $ 999.6 | |
| Member of Scientific Advisory Board | 5.7yrs | no data | no data | |
| Director | 11.8yrs | US$29.50k | 33.85% $ 3.4m | |
| Independent Chairman of the Board | 8.2yrs | US$36.53k | 0.58% $ 57.7k | |
| Independent Director | 5.6yrs | US$32.50k | 0.31% $ 30.9k | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Independent Director | 3.5yrs | US$32.50k | 0.0077% $ 768.7 | |
| Independent Director | 2.3yrs | US$32.00k | 0% $ 0 |
Experienced Board: PURE's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/19 22:17 |
| End of Day Share Price | 2026/08/19 00:00 |
| Earnings | 2026/04/30 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PURE Bioscience, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keith Markey | Griffin Securities |